Table 1.
Study subject demographics and baseline clinical characteristics
| fT>MIC sufficient (n=14) | fT>MIC not sufficient (n=13) | P value | |
| Age,* predicted mean years (SE) | 9.7 (1.3) | 10.2 (1.3) | 0.788 |
| Gender† (n, % female) | 8 (57) | 4 (31) | 0.168 |
| Race,† n (%) | 0.076 | ||
| White | 10 (71) | 12 (92) | |
| Black | 4 (29) | 0 (0) | |
| Other | 0 (0) | 1 (8) | |
| Ethnicity,† n (%) | 0.345 | ||
| Hispanic | 4 (29) | 6 (46) | |
| Not Hispanic | 10 (71) | 7 (54) | |
| CFTR genotype,† n (%) | 0.020 | ||
| F508del homozygous | 3 (21) | 9 (69) | |
| F508del heterozygous | 7 (50) | 4 (31) | |
| Other | 4 (29) | 0 (0) | |
| Disease stage,† n (%) | 0.511 | ||
| Early (FEV1>70%) | 12 (86) | 11 (84) | |
| Intermediate (FEV1 40%–70%) | 0 (0) | 1 (8) | |
| Advanced (FEV1<40%) | 0 (0) | 0 (0) | |
| NA (age<6 years) | 2 (14) | 1 (8) | |
| BMI,* predicted mean (SE) | 16.7 (1.2) | 17.6 (1.3) | 0.859 |
| Maintenance azithromycin,† n (% yes) | 1 (7) | 3 (23) | 0.244 |
| Maintenance inhaled antibiotic,† n (% yes) | 5 (36) | 5 (38) | 0.833 |
| CFTR modulator,† n (% yes) | 2 (14) | 5 (38) | 0.152 |
| Home insulin,† n (% yes) | 1 (7) | 0 (0) | 0.326 |
| Baseline lung function,‡ predicted mean (SE) | (n=12) | (n=12) | |
| % predicted FEV1 | 86.8 (5.68) | 106.1 (5.68) | 0.053 |
| % predicted FVC | 93.1 (5.79) | 106.8 (5.79) | 0.175 |
| % predicted FEF25–75 | 72.6 (12.66) | 118.8 (12.66) | 0.037 |
*General linear model with Gaussian family and identity link.
†χ2.
‡General linear model with Gaussian family and identity link, controlling for demographic characteristics.
§Square transform.
BMI, Body Mass Index; CFTR, cystic fibrosis transmembrane conductance regulator; FEF25–75, forced expiratory flow 25–75; FEV1, forced expiratory volume in one second; fT>MIC, time above the minimum inhibitory concentration; FVC, forced vital capacity.